je.st
news
Tag: antibody
First Presentation of Early Data for Pembrolizumab (MK-3475), Mercks Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
2014-06-01 15:23:00| Merck.com - Corporate News
Dateline City: CHICAGO Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040) Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned Pembrolizumab Announced as New Generic Name for MK-3475 CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of early findings from a Phase 1b study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as a single-agent (monotherapy) in patients with PD-L1 positive, advanced head and neck cancer. Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
head
early
Seattle Genetics' Antibody Drug Conjugate Tech Prominent at ASCO Meeting
2014-06-01 13:32:00| Biotech - Topix.net
Seattle Genetics, the company that pioneered the antibody-drug conjugate platform in Adcetris, the Hodgkin's lymphoma treatment, has data presented from a handful of collaborator programs at the American Society of Clinical Oncology's 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.
Tags: tech
meeting
drug
seattle
GSK Implements Genedata Biologics as Antibody Discovery Platform
2014-05-28 06:00:00| Industrial Newsroom - All News for Today
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm RD groups and sites<br /> <br /> Basel, Switzerland – Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Biopharm RD at GlaxoSmithKline (GSK) has selected Genedata Biologics™ as a key R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D ...This story is related to the following:Scientific Software |
Tags: platform
discovery
antibody
implements
Mercks Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
2014-05-14 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-nave and treated settings; data included in ASCO Press Program First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer First presentation of findings of MK-3475 in recurrent/metastatic head and neck cancer WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data for the companys investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer, are scheduled to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on May 30 June 3, 2014. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Dotmatics: Instant Antibody Drug Conjugate MS Data Analysis at PEGS 2014
2014-05-07 06:00:00| Industrial Newsroom - All News for Today
BISHOPS STORTFORD, England – Meet Dotmatics at booth #127 to analyse and visualise antibody and drug mass<br /> <br /> Dotmatics, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, will be exhibiting at booth #127 of the 10th Annual PEGS Boston [<a href="http://www.pegsummit.com">http://www.pegsummit.com</a> conference at the Seaport World Trade Center from May 5th - 9th.<br /> <br /> Dotmatics' new Antibody Drug ...This story is related to the following:Scientific Software | Data Analysis Software |
Tags: data
analysis
instant
drug